Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
155,974.00
205,724.00
175,633.00
129,552.00
146,669.00
328,199
Other Current Assets
1,982.00
2,027.00
1,967.00
2,084.00
1,754.00
6,413
Total Current Assets
157,956.00
207,751.00
177,600.00
131,636.00
148,423.00
334,612
Net Property, Plant & Equipment
240.00
2,754.00
3,483.00
2,836.00
2,185.00
3,863
Total Investments and Advances
-
9,058.00
34,360.00
45,913.00
29,686.00
2,717
Other Assets
30.00
774.00
-
-
-
-
Total Assets
158,226.00
220,337.00
215,443.00
180,385.00
180,294.00
341,192
Accounts Payable
1,740.00
-
3,808.00
4,751.00
5,665.00
Other Current Liabilities
1,552.00
12,301.00
11,324.00
11,725.00
43,802.00
Total Current Liabilities
3,292.00
12,301.00
15,132.00
16,476.00
49,467.00
Other Liabilities
-
1,242.00
1,946.00
1,666.00
1,363.00
Total Liabilities
3,292.00
13,543.00
17,078.00
18,142.00
50,830.00
Common Equity (Total)
154,934.00
206,794.00
198,365.00
162,243.00
129,464.00
Total Shareholders' Equity
154,934.00
206,794.00
198,365.00
162,243.00
129,464.00
Total Equity
154,934.00
206,794.00
198,365.00
162,243.00
129,464.00
Liabilities & Shareholders' Equity
158,226.00
220,337.00
215,443.00
180,385.00
180,294.00

About Karyopharm Therapeutics

View Profile
Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.